Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BLISS GVS PHARMA Gains 7%; BSE HEALTHCARE Index Up 0.2%
Thu, 21 Nov 15:22

BLISS GVS PHARMA Gains 7%; BSE HEALTHCARE Index Up 0.2%Image source: Ivcandy/www.istockphoto.com

BLISS GVS PHARMA share price has zoomed 7% and is presently trading at Rs 129.0.

Meanwhile, the BSE HEALTHCARE index is at 42,466.2 (up 0.2%).

Among the top gainers in the BSE HEALTHCARE index today are FORTIS HEALTHCARE (up 3.4%) and KIMS (up 3.1%).

SUN PHARMA ADV. RES. (down 3.0%) and GSK Pharma (down 2.7%) are among the top losers today.

Over the last one year, BLISS GVS PHARMA has moved down from Rs 138.8 to Rs 129.0, registering a loss of Rs 9.8 (down 7.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 29,583.1 to 42,466.2, registering a gain of 43.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 159.9%), SUVEN PHARMACEUTICALS (up 114.6%) and FORTIS HEALTHCARE (up 88.5%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 77,162.3 (down 0.5%).

The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 13.6%) and NTPC (down 2.7%). The most traded stocks in the BSE Sensex are Tata Steel and MUNDRA PORT & SEZ.

In the meantime, NSE Nifty is at 23,349.4 (down 0.7%). Adani Enterprises and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,655.2 to 77,162.3, registering a gain of 11,507.1 points (up 17.5%).

BLISS GVS PHARMA Financial Update...

BLISS GVS PHARMA net profit fell 40.3% YoY to Rs 257 million for the quarter ended September 2024, compared to a profit of Rs 430 million a year ago. Net sales rose 2.7% to Rs 2,177 million during the period as against Rs 2,119 million in July-September 2023.

For the year ended March 2024, BLISS GVS PHARMA reported 6.3% increase in net profit to Rs 816 million compared to net profit of Rs 767 million during FY23. Revenue of the company grew 2.5% to Rs 7,702 million during FY24.

The current Price to earnings ratio of BLISS GVS PHARMA, based on rolling 12 month earnings, stands at 18.9.


Equitymaster requests your view! Post a comment on "BLISS GVS PHARMA Gains 7%; BSE HEALTHCARE Index Up 0.2%". Click here!